EGFR and neoplasm: Indeed, RAS-mutant human tumors, which often have disruption of p53 and other tumor suppressors, typically do not have BRAF or EGFR mutations and vice versa outside of drug resistance settings (Cancer Genome Atlas Research Network et al., 2018).